Progress of esketamine in low opioid general anesthesia strategy in laparoscopic total hysterectomy

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100051465

Enrollment

Unknown

Registered

2021-09-24

Start date

2021-10-01

Completion date

Unknown

Last updated

2023-03-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

laparoscopic total hysterectomy

Interventions

Experimental group:low opioid (esketamine)

Control group:Opioid (remifentanil)

Eligibility

Sex/Gender

Female

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. American society of anesthesiologists (ASA) grades I to II; 2. No analgesic/sedative drugs have been used within 24 hours before surgery; 3. No serious endocrine and cardiovascular system diseases; 4. There is no mental disorder and can cooperate with the experimenter.

Exclusion criteria

Exclusion criteria: 1. Those who have anesthesia drug allergy history and contraindications; 2. Those who have long-term addiction and dependence on opioids or hypnotics; 3. Severe heart, lung, liver and kidney dysfunction.

Design outcomes

Primary

Measure	Time frame
Visual Analog Score;Postoperative recovery quality;	—

Secondary

Measure	Time frame
Comfort Score;	—

Countries

China

Contacts

Public ContactLiu Jialei

The First Affiliated Hospital of Shihezi University

315187572@qq.com+86 18899123100

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026